Background: Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT). Methods: Patients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care. Results: Thirty-four of 35 patients who were ADT-treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P=.02). Conclusion: We recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its response and clinical benefit.

Androgen deprivation therapy, Androgen receptors, Antineoplastic agents, Hormonal, Salivary duct carcinoma, Salivary gland neoplasms
dx.doi.org/10.1002/hed.25035, hdl.handle.net/1765/103642
Head & Neck: journal for the sciences and specialities of the head and neck
Erasmus MC: University Medical Center Rotterdam

Boon, E. (Eline), van Boxtel, W. (Wim), Buter, J, Baatenburg de Jong, R.J, van Es, R.J.J, Bel, M. (Miranda), … Herpen, C.M.L. (2017). Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head & Neck: journal for the sciences and specialities of the head and neck. doi:10.1002/hed.25035